Novasep has in the past two years made several key moves that have resulted in substantial successes.###They include the:###– Announcement of strategic investments with one of the largest chromatography plant in tcalcium citrate 600he world to produce pharmaceutical Omega-3 (completed end 2014) and an antibody-drug conjugate production plant (to be completed in 2016),###– Sales process reorganization to favor the acquisition of strategic projects,###– Development of the biopharma CMO in the immunotherapy and vaccines business,###– Large-scale projzinc gluconate 80 mgect wins confirming the success of the Cobluebonnet calcium citrate magnesium d3mplete Process Line strategy in industrial biotech, and###– Divestment of the Pharmachem plant, significantly de-risking the business.###These changes have led to 7% sales growth to €266 million (US$291.89 million) in 2015 and 3% increase in EBITDA mmanfaat zinc gluconateargin rate (8.5% to 11.5%).###For tnature’s calm magnesium citratehe current year 2016, with its robust backlog, Novasep anticipates further revenue growth in Synthesis, a continuation of the strong revenue level achieved by Biopharma in 2015 and a rebound of Industrial Biotech revenue to historic levels.